A Phase I/II, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Hmpl 453 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 22 Jun 2017 According to a Chi-Med media release, the first drug dose was administered on June 19, 2017.
- 18 Jun 2017 Status changed from not yet recruiting to recruiting.
- 21 Mar 2017 New trial record